Share-based Payment Arrangement, Expense in USD of Ernexa Therapeutics Inc. from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Ernexa Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2012 to Q3 2025.
  • Ernexa Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $293K, a 27.7% decline year-over-year.
  • Ernexa Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $1.57M, a 23.4% increase year-over-year.
  • Ernexa Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1.52M, a 22.4% increase from 2023.
  • Ernexa Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1.24M, a 57.7% decline from 2022.
  • Ernexa Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.94M, a 43.9% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Ernexa Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1.57M $293K -$112K -27.7% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025
Q2 2025 $1.69M $368K -$55K -13% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025
Q1 2025 $1.74M $502K +$220K +78% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 $1.52M $410K +$245K +148% 01 Oct 2024 31 Dec 2024 10-K 12 Mar 2025
Q3 2024 $1.28M $405K +$231K +133% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025
Q2 2024 $1.04M $423K +$209K +97.7% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025
Q1 2024 $835K $282K -$407K -59.1% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 $1.24M $165K -$232K -58.4% 01 Oct 2023 31 Dec 2023 10-K 12 Mar 2025
Q3 2023 $1.47M $174K -$302K -63.4% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 $1.78M $214K -$665K -75.7% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 $2.44M $689K -$494K -41.8% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024
Q4 2022 $2.94M $397K -$1.79M -81.8% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024
Q3 2022 $4.72M $476K -$1.25M -72.5% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 $5.97M $879K -$275K -23.8% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023
Q1 2022 $6.25M $1.18M +$1.01M +600% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 $5.24M $2.18M +$2.16M +9475% 01 Oct 2021 31 Dec 2021 10-K 20 Mar 2023
Q3 2021 $3.07M $1.73M +$1.71M +7505% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 $1.37M $1.15M +$1.13M +4976% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022
Q1 2021 $237K $169K +$146K +643% 01 Jan 2021 31 Mar 2021 10-Q 17 May 2021
Q4 2020 $91K $22.8K 01 Oct 2020 31 Dec 2020 10-K/A 01 Jul 2022
Q3 2020 $22.7K 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 $22.7K 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021
Q1 2020 $22.7K 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021
Q1 2015 $99K +$47K +90.4% 01 Jan 2015 31 Mar 2015 10-Q 08 May 2015
Q1 2014 $52K 01 Jan 2014 31 Mar 2014 10-Q 08 May 2015

Ernexa Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $1.52M +$278K +22.4% 01 Jan 2024 31 Dec 2024 10-K 12 Mar 2025
2023 $1.24M -$1.69M -57.7% 01 Jan 2023 31 Dec 2023 10-K 12 Mar 2025
2022 $2.94M -$2.3M -43.9% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024
2021 $5.24M +$5.14M +5653% 01 Jan 2021 31 Dec 2021 10-K 20 Mar 2023
2020 $91K 01 Jan 2020 31 Dec 2020 10-K/A 01 Jul 2022
2013 $132K -$53K -28.6% 01 Jan 2013 31 Dec 2013 10-K 31 Mar 2014
2012 $185K 01 Jan 2012 31 Dec 2012 10-K 31 Mar 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.